MX2012004286A - Combinaciones de un inhibidor de pi3k y un inhibidor de mek. - Google Patents
Combinaciones de un inhibidor de pi3k y un inhibidor de mek.Info
- Publication number
- MX2012004286A MX2012004286A MX2012004286A MX2012004286A MX2012004286A MX 2012004286 A MX2012004286 A MX 2012004286A MX 2012004286 A MX2012004286 A MX 2012004286A MX 2012004286 A MX2012004286 A MX 2012004286A MX 2012004286 A MX2012004286 A MX 2012004286A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combinations
- pi3k
- mek
- kinase
- Prior art date
Links
- 229940124647 MEK inhibitor Drugs 0.000 title 1
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 abstract 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 abstract 2
- 102000038030 PI3Ks Human genes 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 208000037843 metastatic solid tumor Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención se refiere a métodos para tratar un paciente que tiene tumores sólidos localmente avanzados o me-tastásicos con una combinación de un inhibidor de fosfatidi-linositol-3-quinasa (PI 3-quinasa o PI3K) y un inhibidor de proteína-quinasa-quinasa activada con mitógeno (MEK) aquí descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25085209P | 2009-10-12 | 2009-10-12 | |
PCT/EP2010/065149 WO2011054620A1 (en) | 2009-10-12 | 2010-10-11 | Combinations of a pi3k inhibitor and a mek inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012004286A true MX2012004286A (es) | 2012-05-22 |
MX345155B MX345155B (es) | 2017-01-18 |
Family
ID=43072663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012004286A MX345155B (es) | 2009-10-12 | 2010-10-11 | Combinaciones de un inhibidor de pi3k y un inhibidor de mek. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110086837A1 (es) |
EP (1) | EP2488178B1 (es) |
JP (2) | JP2013507415A (es) |
KR (1) | KR101489045B1 (es) |
CN (1) | CN102740851B (es) |
AR (1) | AR078588A1 (es) |
AU (1) | AU2010314287A1 (es) |
BR (1) | BR112012008483A2 (es) |
CA (1) | CA2776944A1 (es) |
CL (1) | CL2012000913A1 (es) |
CO (1) | CO6531463A2 (es) |
CR (1) | CR20120173A (es) |
EC (1) | ECSP12011865A (es) |
ES (1) | ES2609767T3 (es) |
HK (1) | HK1175125A1 (es) |
IL (1) | IL219105A0 (es) |
MA (1) | MA33974B1 (es) |
MX (1) | MX345155B (es) |
NZ (1) | NZ599939A (es) |
PE (1) | PE20121816A1 (es) |
RU (1) | RU2563193C2 (es) |
TW (1) | TWI428336B (es) |
WO (1) | WO2011054620A1 (es) |
ZA (1) | ZA201202618B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011000440A (es) | 2008-07-11 | 2011-02-24 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
DK2385832T3 (en) | 2009-01-08 | 2015-09-21 | Curis Inc | Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel |
US9682991B2 (en) | 2009-12-31 | 2017-06-20 | Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii | Tricyclic compounds for use as kinase inhibitors |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
SG10201602569RA (en) | 2011-04-01 | 2016-05-30 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
EA026924B1 (ru) * | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
AU2012333092B2 (en) * | 2011-08-31 | 2016-04-21 | Novartis Ag | Synergistic combinations of PI3K- and MEK-inhibitors |
CN103957902A (zh) | 2011-10-13 | 2014-07-30 | 基因泰克公司 | 药理学诱导的胃酸过少的治疗 |
MX2014004991A (es) * | 2011-10-28 | 2014-05-22 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma. |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
AU2013243429A1 (en) * | 2012-04-06 | 2014-10-23 | Merck Patent Gmbh | Methods for treating cancer using PI3K inhibitor and MEK inhibitor |
US9566307B2 (en) | 2012-04-19 | 2017-02-14 | Kyushu University, National University Corporation | Pharmaceutical composition |
EP3545968A1 (en) | 2012-06-08 | 2019-10-02 | F. Hoffmann-La Roche AG | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
BR112015002193A2 (pt) | 2012-08-02 | 2017-07-04 | Genentech Inc | anticorpos anti-etbr e imunoconjugados |
MX2015001407A (es) | 2012-08-02 | 2015-05-08 | Genentech Inc | Inmunoconjugados y anticuerpos anti-etbr. |
CA2879252C (en) * | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
EP2968540A2 (en) * | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
ES2945387T3 (es) | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
AR101210A1 (es) | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
CN113620978A (zh) * | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
US11234986B2 (en) | 2018-09-11 | 2022-02-01 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
CN110420330B (zh) * | 2019-07-19 | 2020-05-29 | 南京医科大学 | 一种pi3k与mth1靶向药组合物的制药用途 |
JP2022547358A (ja) | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
BE759493A (fr) * | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
CH592668A5 (es) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4510139A (en) * | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
US6048885A (en) * | 1994-04-01 | 2000-04-11 | Shionogi & Co., Ltd. | Oxime derivative and bactericide containing the same as active ingredient |
US6974878B2 (en) * | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
GEP20053496B (en) * | 2000-07-19 | 2005-04-25 | Warner Lambert Co | Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
JP5129143B2 (ja) * | 2005-10-07 | 2013-01-23 | エグゼリクシス, インコーポレイテッド | Mekインヒビターおよびその使用方法 |
AU2007246793B2 (en) * | 2006-04-26 | 2013-02-07 | F. Hoffmann-La Roche Ag | Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor |
CN104784695A (zh) * | 2006-08-16 | 2015-07-22 | 埃克塞利希斯股份有限公司 | 使用pi3k和mek调控剂的方法 |
NZ578162A (en) * | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
JP6147246B2 (ja) * | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
-
2010
- 2010-10-11 JP JP2012533589A patent/JP2013507415A/ja not_active Ceased
- 2010-10-11 AU AU2010314287A patent/AU2010314287A1/en not_active Abandoned
- 2010-10-11 WO PCT/EP2010/065149 patent/WO2011054620A1/en active Application Filing
- 2010-10-11 CN CN2010800563069A patent/CN102740851B/zh not_active Expired - Fee Related
- 2010-10-11 CA CA2776944A patent/CA2776944A1/en not_active Abandoned
- 2010-10-11 KR KR1020127012069A patent/KR101489045B1/ko not_active IP Right Cessation
- 2010-10-11 PE PE2012000470A patent/PE20121816A1/es not_active Application Discontinuation
- 2010-10-11 US US12/902,062 patent/US20110086837A1/en not_active Abandoned
- 2010-10-11 RU RU2012118974/15A patent/RU2563193C2/ru not_active IP Right Cessation
- 2010-10-11 EP EP10768448.2A patent/EP2488178B1/en active Active
- 2010-10-11 TW TW099134615A patent/TWI428336B/zh not_active IP Right Cessation
- 2010-10-11 MA MA34821A patent/MA33974B1/fr unknown
- 2010-10-11 BR BR112012008483A patent/BR112012008483A2/pt not_active IP Right Cessation
- 2010-10-11 ES ES10768448.2T patent/ES2609767T3/es active Active
- 2010-10-11 MX MX2012004286A patent/MX345155B/es active IP Right Grant
- 2010-10-11 NZ NZ599939A patent/NZ599939A/en not_active IP Right Cessation
- 2010-10-12 AR ARP100103706A patent/AR078588A1/es not_active Application Discontinuation
-
2012
- 2012-04-05 IL IL219105A patent/IL219105A0/en unknown
- 2012-04-10 CR CR20120173A patent/CR20120173A/es unknown
- 2012-04-11 ZA ZA2012/02618A patent/ZA201202618B/en unknown
- 2012-04-11 CL CL2012000913A patent/CL2012000913A1/es unknown
- 2012-04-20 CO CO12065784A patent/CO6531463A2/es not_active Application Discontinuation
- 2012-05-03 EC ECSP12011865 patent/ECSP12011865A/es unknown
-
2013
- 2013-03-04 HK HK13102634.3A patent/HK1175125A1/xx not_active IP Right Cessation
-
2014
- 2014-10-01 JP JP2014202819A patent/JP5745678B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110086837A1 (en) | 2011-04-14 |
RU2563193C2 (ru) | 2015-09-20 |
RU2012118974A (ru) | 2013-11-20 |
BR112012008483A2 (pt) | 2019-09-24 |
KR20120064132A (ko) | 2012-06-18 |
JP2015038110A (ja) | 2015-02-26 |
IL219105A0 (en) | 2012-06-28 |
PE20121816A1 (es) | 2013-01-02 |
EP2488178A1 (en) | 2012-08-22 |
CA2776944A1 (en) | 2011-05-12 |
AU2010314287A1 (en) | 2012-05-03 |
ZA201202618B (en) | 2014-10-29 |
AU2010314287A2 (en) | 2012-07-12 |
KR101489045B1 (ko) | 2015-02-02 |
TWI428336B (zh) | 2014-03-01 |
MX345155B (es) | 2017-01-18 |
AR078588A1 (es) | 2011-11-16 |
HK1175125A1 (en) | 2013-06-28 |
ES2609767T3 (es) | 2017-04-24 |
CN102740851B (zh) | 2013-12-18 |
ECSP12011865A (es) | 2012-06-29 |
EP2488178B1 (en) | 2016-11-16 |
TW201118082A (en) | 2011-06-01 |
CL2012000913A1 (es) | 2012-09-14 |
CR20120173A (es) | 2012-07-04 |
CN102740851A (zh) | 2012-10-17 |
CO6531463A2 (es) | 2012-09-28 |
MA33974B1 (fr) | 2013-02-01 |
JP5745678B2 (ja) | 2015-07-08 |
NZ599939A (en) | 2014-02-28 |
JP2013507415A (ja) | 2013-03-04 |
WO2011054620A1 (en) | 2011-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012004286A (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek. | |
MX346379B (es) | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. | |
PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
GB201020860D0 (en) | Disulfiram formulation and uses thereof | |
NZ595572A (en) | Inhibitors of pi3 kinase and / or mtor | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
HK1130438A1 (en) | Using pi3k and mek modulators in treatments of cancer | |
IN2012DN03012A (es) | ||
CO6620019A2 (es) | Métodos de tratamiento de cander de vejiga | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
IL182423A0 (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
WO2010146059A3 (en) | Biomarkers for igf-1r inhibitor therapy | |
MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
CL2011002569A1 (es) | Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r. | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
MX2013015357A (es) | Terapia de combinacion. | |
MX2010004259A (es) | Tratamientos antitumorales mejorados. | |
CL2011003248A1 (es) | Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |